Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | MMP12 | P39900 | 1/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.33 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.33 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.33 |
| ▸ | MMP8 | P22894 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13156166 | 0.82 | GAA (0.38) | PTGS1 | |
| SCHEMBL24000070 | 0.81 | — | — | |
| SCHEMBL16622303 | 0.81 | CA2 (0.35) | CA2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL18051751 | 0.80 | CA2 (0.38) | CA2KDM4EPTGS1MMP12HDAC3 | |
| SCHEMBL18874574 | 0.77 | RIPK1 (0.34) | MMP8 | |
| SCHEMBL16622294 | 0.77 | MMP8 (0.38) | CA2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL20625818 | 0.76 | MMP8 (0.37) | CA2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL18530841 | 0.74 | KDM4C (0.40) | KDM4E | |
| SCHEMBL15499322 | 0.73 | KDM4E (0.40) | CA2KDM4EHDAC3HDAC4HDAC1 | |
| SCHEMBL7158188 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3783014-A1 | ACYLATED GLP-1 DERIVATIVE | Sciwind Biosciences Co., Ltd. (CN) | 2021-02-24 | — | — | EP | disclosed |
| US-9012398-B2 | Acylated exendin-4 compounds | NOVO NORDISK A/S (DK) | 2015-04-21 | — | — | US | disclosed |
| US-8536122-B2 | Acylated GLP-1 compounds | NOVO NORDISK A/S (DK) | 2013-09-17 | — | — | US | disclosed |
| US-20120295847-A1 | Acylated GLP-1 Compounds | NOVO NORDISK A/S (DK) | 2012-11-22 | — | — | US | disclosed |
| US-20120283170-A1 | Acylated Exendin-4 Compounds | NOVO NORDISK A/S (DK) | 2012-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295847-A1 | Acylated GLP-1 Compounds | GLP1R, GIPR, GCGR | CA2 4167/4885KDM4E 2955/4885PTGS1 1166/4885 |
| US-20120283170-A1 | Acylated Exendin-4 Compounds | GLP1R, VIP, IAPP | CA2 4022/4885KDM4E 551/4885PTGS1 1864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.